JNJ-63533054 is a compound under extensive investigation in the medical field, particularly as a selective inhibitor of the enzyme phosphodiesterase 2A (PDE2A). It shows potential in treating neurological disorders such as Alzheimer's disease and depression. Inhibition of PDE2A helps improve neural function and memory by increasing levels of intracellular signaling molecules in neurons, such as cGMP. Preliminary research also suggests it may benefit other psychiatric conditions, like schizophrenia, due to its effects on balancing neurotransmitters in the brain. Clinical studies are ongoing to evaluate its efficacy and safety in humans.